Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Sysmex to offer breast cancer in-vitro diagnostic reagent in Japan for the first time

Sysmex America : 23 June, 2008  (New Product)
Sysmex has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) to manufacture and sell a reagent used for detecting breast cancer metastasis to the lymph nodes as an in-vitro diagnostic agent.
During surgery for early-stage breast cancer, it has been normal procedure to determine whether or not cancer has metastasized to the lymph node by performing a histopathological diagnosis based on microscopic observation. By integrating use of the reagent with our dedicated analyser this procedure can now be performed automatically in Japan for the first time.

The onset of the ageing society is accompanied by increasing cases of cancer and lifestyle-related diseases. At the same time, there is mounting interest in maintaining quality of life (QOL) and good health over the entire span of a human life. In addition, in the USA and Europe as well as in Japan, authorities are deploying medical policies that represent a shift of emphasis from therapy to prevention, in order to extend healthy lifespan and curtail medical costs.

Realising that examinations will assume even more importance for early detection of disease and prevention of recurrence, we at Sysmex have focused on the life science field from early on. We are applying our technical expertise gained in life science to the creation of examination technology that can contribute to improving patient QOL. Such improvement in QOL is needed by patients throughout the world, so we believe that the new technology will generate new markets and help to equalise medical services. Paying particular attention to the area of cancer, we are developing new examination techniques that utilise technology used for analyzing the action of genes and proteins and enables disease management for cancer.

Where surgery is used for early-stage breast cancer, it has been normal procedure to make a histopathological diagnosis twice (during and after the operation) in order to determine whether or not the cancer has spread to the lymph nodes. The findings of these two examinations provide a basis for decisions regarding subsequent treatment options such as the extent of excision required and post-operative adjuvant therapy. The procedure is associated with several drawbacks, however, such as the need to perform the procedure within a limited time during the operation and the difficulty of determining the presence or absence of metastasis. The situation is compounded by the shortage of skilled pathologists, and has become one of the problems confronting the treatment of breast cancer.

Based on the one-step nucleic acid amplification (OSNA) method that Sysmex developed, our system for rapid detection of breast cancer lymph node metastasis (comprising the gene amplification detector RD-100i used in conjunction with the gene amplification reagent LYNOAMP BC) delivers results with the same level of precision as the conventional procedure in about 30 minutes. Intra-operative detection of metastasis to the lymph nodes in surgery for early-stage breast cancer enables excision of the affected lymph node during the same operation, and therefore helps to lighten the burden on patients by lessening the need for resurgery while lowering the risk of recurrence.

Furthermore, the automation and simplification of the biopsy make it possible to obtain objective results that are not dependent on the skill level of the operator. As such, the system will reduce the workload imposed on pathologists and help to standardise the diagnosis and treatment of breast cancer.

For the future, we are going to work for the prompt market introduction and diffusion of the system and also strive to extend the application of this technology to the detection of metastasis in gastric, colon, and other types of cancer.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo